EXACT THERAPEUTICS AS announced a collaboration with GE Healthcare to develop an innovative ultrasound probe to be used in forthcoming studies using Acoustic Cluster Therapy (ACT®) across multiple disease conditions. ACT® is a proprietary formulation consisting of microbubbles and microdroplets that are activated through the application of ultrasound with the consequent increase in targeted delivery of a co-administered therapeutic agent. ACT® is supported by a strong and broad preclinical package demonstrating therapeutic enhancement in multiple oncology models (pancreatic, breast, colon, prostate) as well as controlled blood-brain barrier opening. Currently ACT® is being evaluated in the international ACTIVATE Phase I clinical trial in patients with metastatic colorectal and pancreatic cancer at the Royal Marsden Hospital in London.